2023年中国流感病毒裂解疫苗行业概览：百万需求疫苗产品更替，赛道企业注重四价布局

Industry Overview - The Chinese influenza virus split vaccine industry has experienced rapid growth, with the market size increasing from RMB 1.07 billion in 2018 to RMB 6.92 billion in 2022, representing a compound annual growth rate (CAGR) of 59.5% [3] - The market is expected to grow from RMB 6.7 billion in 2023 to RMB 10.36 billion by 2027, with a CAGR of 11.5% [3] - The large base of influenza patients in China drives the demand for influenza virus split vaccines, with reported cases increasing from 457,000 in 2017 to 2.443 million in 2022, a CAGR of 39.8% [4] Market Drivers - The shift from trivalent to quadrivalent vaccines is a key driver of market growth, with the proportion of quadrivalent vaccine approvals increasing from 32.7% in 2018 to 67.7% in 2022 [5] - Major companies such as Hualan Biological, Jindike Biological, Changchun Biological, and Sinovac have launched quadrivalent vaccines, which offer broader immune coverage and higher market acceptance [5][6] - The trend of quadrivalent vaccines replacing trivalent ones is accelerating, with several companies reducing or halting trivalent vaccine production in favor of quadrivalent vaccines [6] Competitive Landscape - The industry is highly concentrated, with the top four companies (CR4) holding over 75% of the market share [39] - Hualan Biological, Sinovac, and Changchun Biological are the leading players, with market shares of 43.0%, 22.7%, and 12.9% respectively in 2023 [39] - Several companies, including Zhifei Biological, Yalifeng Biological, and Tianyuan Biological, are advancing their quadrivalent vaccine development, with some already in Phase III clinical trials [40][41] Key Players - Hualan Biological is a leader in the influenza vaccine market, being the first to launch a quadrivalent vaccine in China and expanding its production capacity to 100 million doses [44] - Sinovac is a vaccine industry leader with a diverse product pipeline, including both trivalent and quadrivalent influenza vaccines [45] - Changchun Biological has a strong R&D capability and a broad portfolio of biological products, including influenza vaccines [46] Future Trends - The quadrivalent influenza vaccine market is expected to see intensified competition as more companies advance their R&D and production capabilities [40] - Government policies and increasing public awareness of vaccination are expected to further drive market growth, with local governments implementing free vaccination programs for high-risk groups [19] - China's influenza vaccination rate remains low compared to developed countries, indicating significant growth potential for the market [31]